TransCode Therapeutics (NASDAQ:RNAZ) Issues Quarterly Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) released its earnings results on Monday. The company reported ($9.19) earnings per share (EPS) for the quarter, Zacks reports.

TransCode Therapeutics Stock Performance

Shares of NASDAQ:RNAZ traded down $0.07 on Wednesday, hitting $1.33. 16,496 shares of the company were exchanged, compared to its average volume of 104,455. The company’s 50 day moving average price is $1.64 and its two-hundred day moving average price is $5.65. The firm has a market capitalization of $22.60 million, a price-to-earnings ratio of -0.03 and a beta of 1.24. TransCode Therapeutics has a one year low of $1.28 and a one year high of $12.60.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Read Our Latest Research Report on TransCode Therapeutics

TransCode Therapeutics Company Profile

(Get Free Report)

TransCode Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for cancer, with a focus on metastatic disease. Its research centers on using RNA therapeutics to target biological processes involved in cancer growth and spread. The company’s lead program, TTX-MC138, is designed to inhibit microRNA-10b, a molecule associated with cancer metastasis. TransCode is also advancing other investigational RNA-based programs aimed at cancer-related targets. These candidates remain in development and are not approved treatments.

Featured Stories

Earnings History for TransCode Therapeutics (NASDAQ:RNAZ)

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.